Khiron Life Sciences Corp. (KHRNF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.4 Million | -24.53 Million | -30.07 Million | -14.77 Million | -21.3 Thousand | -58.22 Thousand |
| Net Income | -33.59 Million | -23.94 Million | -36.35 Million | -19.8 Million | -44.68 Thousand | -59.55 Thousand |
| Depreciation & Amortization | 1.11 Million | 1.16 Million | 938.53 Thousand | 337.91 Thousand | - | - |
| Deferred income taxes | 13.16 Million | - | - | 78.58 Thousand | - | - |
| Stock-based compensation | 2322.00 | 5716.00 | 9371.09 | - | - | - |
| Change in working capital | -2.32 Million | -1.93 Million | -3.18 Million | 1.32 Million | 23.37 Thousand | 1336.00 |
| Other non-cash items | -1.08 Million | -5.52 Million | -847.05 Thousand | - | - | - |
| Investing Cash Flow | -2.08 Million | 24.86 Million | -31.97 Million | -9.21 Million | - | 25 Thousand |
| Investments in PPE | -1.74 Million | -2.69 Million | -6.09 Million | -3.82 Million | - | - |
| Acquisitions | -342 Thousand | - | -2.83 Million | -1.44 Million | - | - |
| Investment purchases | - | - | -23.05 Million | -3.94 Million | - | - |
| Sales/Maturities of investments | - | 27.55 Million | 23.05 Million | - | - | - |
| Other Investing Activities | -342 Thousand | 27.56 Thousand | -23.05 Million | - | - | 25 Thousand |
| Financing Cash Flow | 10.89 Million | 12.17 Million | 56.99 Million | 37.58 Million | 5000.00 | - |
| Debt repayment | -107 Thousand | -555.19 Thousand | -1.27 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -212.38 Thousand | - | - | - | - |
| Common Stock Issuance | 11 Million | 12.93 Million | 53.13 Million | 905 Thousand | 5000.00 | - |
| Other Financing Activities | 11 Thousand | 12.94 Thousand | 5.12 Million | 36.68 Million | - | - |
| Accounts receivables | 2.3 Million | 605.75 Thousand | -1.38 Million | 834.15 Thousand | - | - |
| Accounts payables | -2.83 Million | -1.86 Million | 848.9 Thousand | - | - | - |
| Inventory | -1.44 Million | -2.06 Million | -700.44 Thousand | -181.22 Thousand | - | - |
| Other working capital | -360 Thousand | 1.38 Million | -1.94 Million | 673.82 Thousand | - | - |
| Cash at beginning of period | 21.64 Million | 9.34 Million | 15.01 Million | 1.8 Million | 21.26 Thousand | 54.48 Thousand |
| Cash at end of period | 8.92 Million | 21.64 Million | 9.34 Million | 15.01 Million | 4960.00 | 21.26 Thousand |
| Capital Expenditure | -1.74 Million | -2.69 Million | -6.09 Million | -3.82 Million | - | - |
| Effect of forex changes on cash | -1.13 Million | -202.34 Thousand | -612.86 Thousand | -387.26 Thousand | - | - |
| Net cash flow / Change in cash | -12.72 Million | 12.3 Million | -5.66 Million | 13.2 Million | -16.3 Thousand | -33.22 Thousand |
| Free Cash Flow | -22.14 Million | -27.22 Million | -36.16 Million | -18.59 Million | -21.3 Thousand | -58.22 Thousand |
| Breakdown | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 FY | 2021 Q4 | 2021 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.45 Million | -2.2 Million | -5.41 Million | -33.59 Million | -19.95 Million | -3.33 Million |
| Depreciation & Amortization | 556 Thousand | 653 Thousand | 596 Thousand | 1.11 Million | 151.44 Thousand | 341.16 Thousand |
| Deferred income taxes | - | - | - | 13.16 Million | 14.4 Million | -1.23 Million |
| Stock-based compensation | 328.00 | 338 Thousand | 309 Thousand | 2322.00 | -246.18 Thousand | 535.16 Thousand |
| Change in working capital | -2.02 Million | 1 Million | 351 Thousand | -2.32 Million | 192.94 Thousand | -1.03 Million |
| Other non-cash items | -450 Thousand | -1.78 Million | 1.35 Million | -1.08 Million | 288.69 Thousand | -119.12 Thousand |
| Investing Cash Flow | -872 Thousand | -474 Thousand | -309 Thousand | -2.08 Million | -1.47 Million | -213.97 Thousand |
| Investments in PPE | -873 Thousand | -465 Thousand | -317 Thousand | -1.74 Million | -1.12 Million | -213.97 Thousand |
| Acquisitions | - | -8000.00 | 8000.00 | -342 Thousand | -342 Thousand | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 1000.00 | -1000.00 | 8000.00 | -342 Thousand | -342 Thousand | - |
| Financing Cash Flow | 864 Thousand | 3.6 Million | -194 Thousand | 10.89 Million | 471.1 Thousand | 11.25 Million |
| Debt repayment | -169 Thousand | -254 Thousand | -303 Thousand | -107 Thousand | -641.01 Thousand | -84.28 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 3.86 Million | - | 11 Million | -1.34 Million | 11 Million |
| Other Financing Activities | 1.03 Million | 3.86 Million | 109 Thousand | 11 Thousand | 2.45 Million | 11.34 Million |
| Accounts receivables | -191 Thousand | -241 Thousand | -1.36 Million | 2.3 Million | 3.21 Million | -247.09 Thousand |
| Accounts payables | -1.73 Million | 409 Thousand | 1.97 Million | -2.83 Million | -2.1 Million | -1.24 Million |
| Inventory | 118 Thousand | 97 Thousand | -150 Thousand | -1.44 Million | -324.5 Thousand | -358.32 Thousand |
| Other working capital | -218 Thousand | 737 Thousand | 1.86 Million | -360 Thousand | -2.69 Million | -433.05 Thousand |
| Cash at beginning of period | 5.81 Million | 5.12 Million | 8.92 Million | 21.64 Million | 15.42 Million | 9.35 Million |
| Cash at end of period | 1.93 Million | 5.81 Million | 5.12 Million | 8.92 Million | 8.92 Million | 15.42 Million |
| Capital Expenditure | -873 Thousand | -465 Thousand | -317 Thousand | -1.74 Million | -1.12 Million | -213.97 Thousand |
| Effect of forex changes on cash | 1.17 Million | -445 Thousand | -490 Thousand | -1.13 Million | -334.56 Thousand | -122.77 Thousand |
| Net cash flow / Change in cash | -3.88 Million | 691 Thousand | -3.79 Million | -12.72 Million | -6.5 Million | 6.06 Million |
| Free Cash Flow | -5.91 Million | -2.46 Million | -3.12 Million | -22.14 Million | -6.29 Million | -5.06 Million |
6054
8511
KIT
300694
069620
TCRRF